GlassScriptPhysician profile
Wei Y Sun
NPI 1588633135
$56,641.63
in general payments reported to CMS, 2019-2025
57 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,319 · 2020: $2,090 · 2021: $3,849 · 2022: $9,680 · 2023: $4,177 · 2024: $22K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $15K · Education: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,400.00 |
| Food and Beverage | $14,714.28 |
| Education | $589.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $22,364.25 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $5,573.22 | 2021-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $3,960.67 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,640.03 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $1,838.90 | 2019-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $1,756.14 | 2019-2025 | Ozempic, Rybelsus, Rivfloza |
| Abbvie INC. | $1,538.60 | 2019-2025 | Linzess, Viberzi |
| Mallinckrodt Hospital Products INC. | $1,078.71 | 2020-2025 | Acthar |
| Vifor Pharma, INC. | $1,072.18 | 2019-2025 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $952.09 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $950.02 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $884.68 | 2021-2025 | Lupkynis |
| Amarin Pharma, INC. | $882.86 | 2019-2023 | |
| Amgen INC. | $861.84 | 2019-2025 | Tavneos, Krystexxa, Uplizna |
| Glaxosmithkline, LLC. | $831.31 | 2021-2025 | Benlysta, Jesduvroq |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.